Donald Picker - Cns Pharmaceuticals Chief Officer
| CNSP Stock | USD 0.14 0.03 27.27% |
Insider
Donald Picker is Chief Officer of Cns Pharmaceuticals
| Age | 79 |
| Address | 2100 West Loop South, Houston, TX, United States, 77027 |
| Phone | 800 946 9185 |
| Web | https://www.cnspharma.com |
Donald Picker Latest Insider Activity
Tracking and analyzing the buying and selling activities of Donald Picker against Cns Pharmaceuticals stock is an integral part of due diligence when investing in Cns Pharmaceuticals. Donald Picker insider activity provides valuable insight into whether Cns Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Cns Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Cns Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Donald Picker over a month ago Acquisition by Donald Picker of 16167 shares of Moleculin Biotech subject to Rule 16b-3 | ||
Donald Picker over two months ago Acquisition by Donald Picker of 65000 shares of Moleculin Biotech subject to Rule 16b-3 | ||
Donald Picker over six months ago Acquisition by Donald Picker of 64667 shares of Moleculin Biotech subject to Rule 16b-3 |
Cns Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (2.24) % which means that it has lost $2.24 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.1878) %, meaning that it created substantial loss on money invested by shareholders. Cns Pharmaceuticals' management efficiency ratios could be used to measure how well Cns Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 02/16/2025, Return On Capital Employed is likely to grow to 5.14, though Return On Tangible Assets are likely to grow to (12.11). As of 02/16/2025, Total Current Liabilities is likely to grow to about 7.4 M, while Liabilities And Stockholders Equity is likely to drop slightly above 1.9 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Manuel Dafonseca | Sonnet Biotherapeutics Holdings | N/A | |
| Peter Facchini | Enveric Biosciences | 61 | |
| Joseph Tucker | Enveric Biosciences | 56 | |
| LaBella MS | ZyVersa Therapeutics | 66 | |
| BSc BSc | Hepion Pharmaceuticals | 66 | |
| RPh PharmD | Elevation Oncology | 40 | |
| Nandan BS | Immix Biopharma | 63 | |
| Brian Sullivan | Elevation Oncology | N/A | |
| MD FACP | Sonnet Biotherapeutics Holdings | 67 | |
| Daren Ure | Hepion Pharmaceuticals | N/A | |
| MBA IV | Enveric Biosciences | 68 | |
| MBA MD | Immix Biopharma | 49 | |
| Valerie MD | Elevation Oncology | 47 | |
| Pablo MD | ZyVersa Therapeutics | N/A | |
| Gabriel BA | Immix Biopharma | 38 | |
| Launa Aspeslet | Hepion Pharmaceuticals | N/A | |
| Karen Cashmere | ZyVersa Therapeutics | 73 | |
| Susan Dexter | Sonnet Biotherapeutics Holdings | 70 | |
| DSc MSE | Immix Biopharma | 75 | |
| Sharen Pyatetskaya | Hepion Pharmaceuticals | ||
| Stephen MD | Hepion Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -10.19 | ||||
| Return On Asset | -2.24 |
Cns Pharmaceuticals Leadership Team
Elected by the shareholders, the Cns Pharmaceuticals' board of directors comprises two types of representatives: Cns Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cns. The board's role is to monitor Cns Pharmaceuticals' management team and ensure that shareholders' interests are well served. Cns Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cns Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| JD Esq, President CEO | ||
| Waldemar Priebe, Founder | ||
| Donald Picker, Chief Officer | ||
| CPA CTP, Chief Officer |
Cns Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cns Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -10.19 | ||||
| Return On Asset | -2.24 | ||||
| Current Valuation | 1.11 M | ||||
| Shares Outstanding | 40.75 M | ||||
| Shares Owned By Insiders | 1.20 % | ||||
| Shares Owned By Institutions | 0.70 % | ||||
| Number Of Shares Shorted | 3.63 M | ||||
| Price To Earning | (13.70) X | ||||
| Price To Book | 2.40 X | ||||
| EBITDA | (18.86 M) |
Pair Trading with Cns Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cns Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cns Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Cns Stock
| 0.53 | DRTSW | Alpha Tau Medical | PairCorr |
| 0.39 | LNTH | Lantheus Holdings Earnings Call This Week | PairCorr |
| 0.36 | SLXN | Biomotion Sciences | PairCorr |
| 0.36 | EC | Ecopetrol SA ADR | PairCorr |
| 0.34 | ALC | Alcon AG Sell-off Trend | PairCorr |
The ability to find closely correlated positions to Cns Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cns Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cns Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cns Pharmaceuticals to buy it.
The correlation of Cns Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cns Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cns Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cns Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Cns Stock Analysis
When running Cns Pharmaceuticals' price analysis, check to measure Cns Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cns Pharmaceuticals is operating at the current time. Most of Cns Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cns Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cns Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cns Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.